ZHAOKE OPHTH-B News

Selected Announcements | Alibaba's buyback plan still has a remaining amount of 20.7 billion USD; GTJA plans to conduct a stock swap to absorb and merge HAITONG SEC and will send a proposal to the meeting for fundraising support.

In 2024, Qinhuangdao Port's total throughput reached 0.414 billion tons, a year-on-year increase of 5.66%; ZHAOKE OPHTH-B: The National Medical Products Administration accepted the simplified new drug application for NVK002, used to treat worsening myopia in children.

cls.cnJan 2 19:11 ET

Zhitong Hong Kong stocks early news | China Securities Regulatory Commission: "The rumor that all Bearish will be released before January 15 is false". The S&P and Nasdaq recorded five consecutive declines.

China Securities Regulatory Commission: "Releasing all Bearish before January 15" and "Insurance companies large redemptions of public Funds" are both rumors.

Zhitong FinanceJan 2 18:28 ET

Express News | Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children

ReutersJan 2 05:40 ET

Hong Kong stocks movement | ZHAOKE OPHTH-B (06622) once rose more than 8% as the drug for treating wet age-related macular degeneration reached the primary endpoint in its Phase III clinical trial.

ZHAOKE OPHTH-B (06622) once rose over 8%, as of the time of writing, it increased by 5.83%, priced at 1.27 Hong Kong dollars, with a transaction amount of 0.8308 million Hong Kong dollars.

Zhitong FinanceJan 1 21:56 ET

Zhao Ke Ophthalmology (06622): TAB014 related clinical trials have yielded positive results.

Kingwo Financial News | Zhaoke Ophthalmology (06622) announced that TAB014 (one of the company's core candidate drugs) has positive topline results from the Phase III clinical trial for the treatment of wet (neovascular) age-related macular degeneration (“wAMD”). This clinical trial successfully achieved the primary endpoint and key secondary endpoints. The Phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study, with the main objective of assessing the best corrected visual acuity (BCVA) at week 52 for the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at baseline.

Jingu Finance News.Jan 1 20:08 ET

Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.

On December 9, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that following the approval for marketing of Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, the company's glaucoma product portfolio has recently added three more pharmaceuticals (Latanoprost Eye Drops, Travoprost Eye Drops, and Travoprost Timolol Eye Drops) that have been approved for listing by the National Medical Products Administration ("NMPA"), equivalent to passing the consistency evaluation of generic drugs. These pharmaceuticals are all produced by the company. Together with Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, they constitute a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes its products...

Gelonghui FinanceDec 9, 2024 04:26 ET

Express News | Zhaoke Ophthalmology - Marketing Authorizations Obtained From Nmpa for Latanoprost Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop

ReutersDec 9, 2024 04:23 ET

Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results

MT NewswiresOct 23, 2024 08:50 ET

China Medical Ophthalmology-B (06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) for NVK002, used to treat deepening myopia in children.

Oct 23, Geelong Health | Medigen Eye Care-B (06622.HK) announced that the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products) were released. After two years of treatment, the analysis of this study shows that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with NVK002 eye drop group being superior to the placebo group and showing dose dependence. Both doses of NVK002 demonstrated good safety and patient compliance.

Gelonghui FinanceOct 23, 2024 05:48 ET

Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug

MT NewswiresSep 26, 2024 06:01 ET

Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.

Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.

Gelonghui FinanceSep 26, 2024 04:33 ET

ZHAOKE OPHTH-B: 2024 Interim Report

HKEXSep 23, 2024 04:33 ET · Announcements

Zhaoke Ophthalmology Glaucoma Eye Drops Get Marketing Approval; Shares Rise 3%

MT NewswiresSep 19, 2024 22:28 ET

Chokesee Eye Care-B (06622.HK): Bemei Prostaglandin Eye Drops (Jingbeiqing) approved by the National Medical Products Administration for listing.

Gelonghui, September 20th | Mega Medical Ophthalmology-B (06622.HK) announced that the company's independently developed anti-glaucoma pharmaceutical Beimei Latanoprost Eye Drops (Crystal Bear Clear) has been approved for marketing by the National Medical Products Administration ("NMPA"). According to the disclosure, Beimei Latanoprost Eye Drops (Crystal Bear Clear) is China's first single-dose Latanoprost eye drops without preservatives, used to reduce intraocular pressure in patients with angle-closure glaucoma and high ocular pressure. This pharmaceutical does not contain preservatives, avoiding eye surface damage in glaucoma patients caused by long-term use of preservative-containing medications. At the same time, this medication also helps improve patients

Gelonghui FinanceSep 19, 2024 18:19 ET

Express News | Zhaoke Ophthalmology Ltd - Marketing Authorization for Bimatoprost Eye Drop (®) Obtained From Nmpa

ReutersSep 19, 2024 18:11 ET

Research and development innovation, business cultivation, international perspective, examining the value growth logic of Chaoke Ophthalmology (6622.HK).

Over the next two years, Zhaoke Ophthalmology may usher in a period of intensive performance outbreaks.

Gelonghui FinanceSep 1, 2024 20:43 ET

Understanding the midterm performance of Meitu Eye Care (06622.HK) in 2024 in one picture.

On August 29, MediLink-Bev(06622.HK) announced its 2024 interim performance. Specific performance details will be explained below with a chart.

Gelonghui FinanceAug 29, 2024 07:47 ET

ZHAOKE OPHTH-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEXAug 29, 2024 06:28 ET · Announcements

MegaMedical-B (06622.HK) will hold a board of directors meeting on August 29 to approve the interim performance.

On August 16, Glorious Sun Ophthalmic (6622.HK) announced that the board of directors will hold a meeting on August 29, 2024 to approve the midterm performance of the company and its subsidiaries for the six months ending June 30, 2024 and to publish its announcement.

Gelonghui FinanceAug 16, 2024 05:38 ET

ZHAOKE OPHTH-B: NOTICE OF BOARD MEETING

HKEXAug 16, 2024 05:34 ET · Announcements